Bictegravir/lenacapavir (Bixlenvo) vs Dezecapavir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV capsid · full HIV pipeline

Bictegravir/lenacapavir (Bixlenvo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Partial signal

NCT05502341 · Phase 2/3 · active, not recruiting

This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.

Next expected readout: July 2028 · NCT07908446 (registry estimate)

Reported efficacy

Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)

Result source: NCT05502341

Dezecapavir

Developed by ViiV Healthcare

Phase 2 in HIVsmall molecule
Partial signal

NCT06039579 · Phase 2 · completed

This Phase 2 trial was randomized, double-blind (participant and investigator), and placebo-controlled, with 44 participants allocated across multiple dose groups of VH4004280 and VH4011499. The primary endpoint was the maximum change in plasma HIV-1 RNA during 10-day monotherapy; posted results for VH4011499 show mean declines of about -1.8 to -2.2 log10 in active arms versus -0.18 log10 in placebo, but no p-values or confidence intervals are reported. Because the groups are very small (6-7 active vs 3 placebo) and the statistical significance of the primary comparison is not documented, this constitutes real but limited evidence.

Next expected readout: February 2027 · NCT07934719 (registry estimate)

Reported efficacy

Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969) (unclear)

Result source: NCT06039579

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBictegravir/​lenacapavir (Bixlenvo)Dezecapavir
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT06532656—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06532656—Not reported
CD4 count, change (week 48)—Trial running · NCT06532656—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Dezecapavir
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Dezecapavir
—Not reported

CD4 count, change (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Dezecapavir
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Bictegravir/lenacapavir (Bixlenvo)
Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). NCT05502341 · Phase 2/3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bictegravir/lenacapavir (Bixlenvo): 0 of 4 rows · Dezecapavir: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDezecapavir
Dropout rate
0%Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 17 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%1875 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%625 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%400 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%300 mg + Midazolam (MDZ) PiB
NCT05393271 · Phase 1 · combination
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg Tablet
NCT05393271 · Phase 1 · monotherapy
0%125 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%25 mg PiB
NCT05393271 · Phase 1 · monotherapy
Discontinued due to AEs
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 17 more results
—Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—1875 mg PiB
NCT05393271 · Phase 1 · monotherapy
—625 mg PiB
NCT05393271 · Phase 1 · monotherapy
—400 mg PiB
NCT05393271 · Phase 1 · monotherapy
—300 mg + Midazolam (MDZ) PiB
NCT05393271 · Phase 1 · combination
—200 mg PiB
NCT05393271 · Phase 1 · monotherapy
—200 mg PiB
NCT05393271 · Phase 1 · monotherapy
—200 mg Tablet
NCT05393271 · Phase 1 · monotherapy
—125 mg PiB
NCT05393271 · Phase 1 · monotherapy
—25 mg PiB
NCT05393271 · Phase 1 · monotherapy
Serious AEs
—Dose Level 1a
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 17 more results
0%Dose Level 1
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 1
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Dose Level 2
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
—Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2
0%Pre-specified Dose
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
0%1875 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%625 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%400 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%300 mg + Midazolam (MDZ) PiB
NCT05393271 · Phase 1 · combination
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%200 mg Tablet
NCT05393271 · Phase 1 · monotherapy
0%125 mg PiB
NCT05393271 · Phase 1 · monotherapy
0%25 mg PiB
NCT05393271 · Phase 1 · monotherapy
Most frequent reported AEs
Dose Level 1a
influenza 14.3% (placebo 33.3%)
proteinuria 14.3% (placebo 0%)
rash 14.3% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 14 more results
Dose Level 1
headache 14.3% (placebo 0%)
upper respiratory tract infection 14.3% (placebo 0%)
alanine aminotransferase increased 0% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
Dose Level 2
arthralgia 16.7% (placebo 0%)
dermatophytosis 16.7% (placebo 0%)
ear pain 16.7% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Dose Level 2
asthenia 16.7% (placebo 0%)
dermatitis acneiform 16.7% (placebo 0%)
diarrhoea 16.7% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
Pre-specified Dose
nausea 28.6% (placebo 0%)
alanine aminotransferase increased 14.3% (placebo 0%)
aspartate aminotransferase increased 14.3% (placebo 0%)
NCT06039579 · Phase 2 · combination · HIV · phase 2
Pre-specified Dose
vessel puncture site haematoma 28.6% (placebo 0%)
headache 14.3% (placebo 0%)
hypokalaemia 14.3% (placebo 0%)
NCT06039579 · Phase 2 · monotherapy · HIV · phase 2
1875 mg PiB
total bile acids increased 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
625 mg PiB
gastroenteritis 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
400 mg PiB
dry skin 16.7% (placebo 0%)
skin abrasion 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
300 mg + Midazolam (MDZ) PiB
somnolence 25% (placebo 0%)
dizziness 12.5% (placebo 0%)
feeling abnormal 12.5% (placebo 0%)
NCT05393271 · Phase 1 · combination
200 mg PiB
activated partial thromboplastin time prolonged 33.3% (placebo 0%)
blood triglycerides increased 16.7% (placebo 0%)
lipase increased 16.7% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
200 mg PiB
diarrhoea 33.3% (placebo 0%)
headache 33.3% (placebo 0%)
nausea 33.3% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
200 mg Tablet
medical device site dermatitis 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
125 mg PiB
medical device site dermatitis 16.7% (placebo 0%)
abdominal pain 0% (placebo 0%)
activated partial thromboplastin time prolonged 0% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy
25 mg PiB
blood creatine phosphokinase increased 16.7% (placebo 20%)
haematocrit decreased 16.7% (placebo 0%)
haemoglobin decreased 16.7% (placebo 0%)
NCT05393271 · Phase 1 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dezecapavir

HIV-1 RNA -1.834 vs -0.176 placebo logDose Level 1
absolute change · log
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.797 vs -0.176 placebo logDose Level 2
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
-2.165 vs -0.176 placebo logPre-specified Dose
Maximum change compared to Baseline (Day 1)
NCT06039579 · Phase 2 · combination · HIV · phase 2
HIV-1 RNA -1.801 log @ 1.57wkDose Level 1
absolute change · log
No placebo or comparator arm
NCT06039579 · Phase 2 · combination · HIV · phase 2
show 2 more results
-1.75 log @ 1.57wkDose Level 2
NCT06039579 · Phase 2 · combination · HIV · phase 2
-2.165 log @ 1.57wkPre-specified Dose
NCT06039579 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir/lenacapavir (Bixlenvo)'s landscape · Dezecapavir's landscape